STOCK TITAN
  1. Home
  2. News
  3. INKT

MiNK Therapeutics Inc - INKT STOCK NEWS

Welcome to our dedicated news page for MiNK Therapeutics (Ticker: INKT), a resource for investors and traders seeking the latest updates and insights on MiNK Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MiNK Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MiNK Therapeutics's position in the market.

News
MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR
Rhea-AI Summary
MiNK-215, a novel cellular therapy developed by MiNK Therapeutics, has shown promising results in combating colorectal cancer liver metastases. The therapy, presented at AACR, demonstrated significant anti-tumor activity through various mechanisms, offering hope to patients with treatment-resistant cancer. MiNK-215's collaboration potential with other immunotherapies like botensilimab and balstilimab highlights its versatility and effectiveness in enhancing the anti-tumor response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.38%
Tags
none
-
News
MiNK Reports Fourth Quarter and Year-End 2023 Results
Rhea-AI Summary
MiNK Therapeutics, Inc. (INKT) announced significant advancements in allogeneic iNKT cell therapies for cancer and immune-mediated diseases. Key highlights include the launch of a Phase 2 trial in gastroesophageal cancers, positive clinical data in solid tumors and ARDS, collaboration with Immunoscape, and financial results for Q4 and full-year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
-
News
MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report
Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT) will release its fourth quarter and year-end 2023 financial results on March 21, 2024. The company focuses on developing iNKT cell therapies for cancer and immune-mediated diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.61%
Tags
earnings
News
MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024
Rhea-AI Summary
MiNK-215, an IL-15 armored FAP-targeting CAR-iNKT cell therapy, showed promising results in eradicating tumor cells in human organoid MSS colorectal cancer liver metastases models. The therapy enhanced tumor killing by T cells, depleted immune suppressive cells, and increased CD8+ T cell infiltration, potentially improving outcomes for patients with liver metastases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
clinical trial
-
News
First Refractory Gastric Cancer Patient Dosed in Phase 2 Trial with Novel Combination of MiNK’s Allogeneic INKT Cell Therapy and Agenus’ Botensilimab and Balstilimab
Rhea-AI Summary
MiNK Therapeutics, Inc. (INKT) announces the initiation of a Phase 2 investigator sponsored study for agenT-797 in second line gastroesophageal cancer at Memorial Sloan Kettering Cancer Center. The study aims to address the treatment challenges faced by ~70% of Gastroesophageal Cancer (GEC) patients. The trial involves a novel combination of Allogeneic Cell Therapy with BOT/BAL and aims to evaluate the safety and efficacy of agenT-797 in combination with botensilimab, balstilimab, ramucirumab, and paclitaxel for patients with advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.76%
Tags
clinical trial
-
News
MiNK Therapeutics' AgenT-797 Shows Promising Results in the Treatment of Severe Acute Respiratory Distress, Published in Nature Communications
Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT) announced promising results from a phase 1/2 study of agenT-797 in patients with severe respiratory distress due to SARS-CoV-2. The study showed improved survival rates, with over 70% survival in patients on mechanical ventilation and an 80% survival rate in patients on VV ECMO. AgenT-797 also demonstrated the ability to induce anti-inflammatory biomarkers, prevent secondary infections, and reduce pneumonia by over 80%. The results highlight the potential of allogeneic iNKT cell therapies in treating severe respiratory distress and immune-related diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.2%
Tags
none
News
MiNK’s AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene
Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT) announced a case report highlighting the potential of iNKT cell therapies to treat advanced solid tumors. The study showed a durable confirmed partial response in a patient with gastric cancer refractory to anti-PD1, indicating the unique potential of iNKT cells to overcome resistance to immune checkpoint inhibitors. The company is continuing to advance iNKT cells in this setting and is looking forward to further updates on its solid tumor programs this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.28%
Tags
none
-
News
ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development
Rhea-AI Summary
MiNK Therapeutics, Inc (Nasdaq: INKT) and ImmunoScape collaborate to develop TCR-based therapies for solid tumors, leveraging MiNK's proprietary library of T-cell antigens and ImmunoScape's Deep Immunomics platform. The collaboration aims to accelerate the development of next-generation TCR therapies against novel targets in solid tumors, offering new therapeutic approaches for diverse cancer indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
MiNK Therapeutics Reports Third Quarter 2023 Results
Rhea-AI Summary
MiNK Therapeutics, Inc. (NASDAQ: INKT) reports positive financial results for Q3 2023, highlights data showing durable clinical benefit in solid tumor cancers and potential in severe respiratory distress. AgenT-797 demonstrates improved survival in late-stage metastatic cancer patients. The company plans to expand into autoimmune and inflammatory diseases. A conference call is scheduled for November 9, 2023, at 8:30 a.m. ET.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.72%
Tags
earnings
News
MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023
Rhea-AI Summary
MiNK Therapeutics, Inc. presented new data on their allogeneic cell therapy, agenT-797, at the Society for Immunotherapy of Cancer's Annual Meeting. The therapy showed clinical benefit in heavily pre-treated patients with solid tumors, including long-term disease stabilization and tolerable safety profile. AgenT-797 demonstrated long-term persistence and induced a potent anti-tumor response. Expansion of clinical programs is underway in additional solid tumor settings, and a randomized phase 2 trial in gastric cancer is expected to launch by year-end 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.59%
Tags
none
Stock INKT logo
MiNK Therapeutics Inc

Nasdaq:INKT

INKT Rankings

#4955 Ranked by Market Cap
#4873 Ranked by Stock Gains
N/A Ranked by Dividends

INKT Stock Data

34.17M
10.01M
71.34%
2.99%
0.12%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
New York